Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

ABSTRACT: Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patients might benefit from maintenance therapy post-transplantation, especially for high-risk AML patients. In this mini-review, we will summarize targeted drugs, such as hypomethylating agents, FLT3 inhibitors and isocitrate dehydrogenase inhibitors, as maintenance therapy post-transplantation in AML patients undergoing allo-HSCT.

SUBMITTER: Xuan L 

PROVIDER: S-EPMC7786934 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature